|
| ID |
DDInter822 |
| Drug Type |
small molecule |
| Molecular Formula |
C21H22N6O |
| Molecular Weight |
374.448
|
| Description |
Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of the benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with a low molecular weight, potent inhibitory activity and lacking unstable functionality. The great lipophilicity of this group of compounds brought interest to further modification. This analysis concluded that the presence of p-cyano ureas presented good physicochemical and pharmacokinetic properties from which glasdegib was developed.[A40310]
Glasdegib was developed by Pfizer Inc and approved on November 21, 2018, by the FDA for the treatment of Acute Myeloid Leukemia.[L11935]
|
| ATC Classification |
L01XX63
|
| IUPAC Name |
1-[(2R,4R)-2-(1H-1,3-Benzodiazol-2-Yl)-1-Methylpiperidin-4-Yl]-3-(4-Cyanophenyl)Urea |
| InChI |
Inchi=1S/C21H22N6O/C1-27-11-10-16(24-21(28)23-15-8-6-14(13-22)7-9-15)12-19(27)20-25-17-4-2-3-5-18(17)26-20/H2-9,16,19H,10-12H2,1H3,(H,25,26)(H2,23,24,28)/T16-,19-/M1/S1 |
| InChI Key |
SFNSLLSYNZWZQG-VQIMIIECSA-N |
| Canonical SMILES |
CN1CC[C@H](C[C@@H]1C1=NC2=CC=CC=C2N1)NC(=O)NC1=CC=C(C=C1)C#N |
| Useful Links |
DrugBank
ChEMBL
|